Pricing Log in Create free account

Candel Therapeutics, Inc. (CADL) vs Nuvectis Pharma, Inc. (NVCT)

Candel Therapeutics, Inc. and Nuvectis Pharma, Inc. are both Biotechnology companies. Candel Therapeutics, Inc. and Nuvectis Pharma, Inc. are of similar size ($722.2M and $705.5M). Across the 9 metrics below, Nuvectis Pharma, Inc. leads on 6 and Candel Therapeutics, Inc. on 3.

Valuation

Metric CADL NVCT Biotechnology median
P/E n/m n/m 11.58
P/S 5,473.85 n/m 9.61
P/B 5.42 4.90 2.26
Price to free cash flow n/m n/m 26.41
EV/EBITDA n/m n/m 0.72
EV/Sales 4,277.78 n/m 9.43
Earnings yield (15.28%) (8.97%) (32.28%)
Free cash flow yield (8.37%) (6.49%) (22.27%)

Profitability

Metric CADL NVCT Biotechnology median
Gross margin 0.00% — 68.81%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (81.84%) (66.98%) (50.30%)
Return on assets (56.37%) (57.20%) (45.47%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CADL NVCT Biotechnology median
Revenue growth (TTM) 0.00% — 6.78%
EPS growth (last fiscal year) 58.62% (18.92%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CADL NVCT Biotechnology median
Debt to equity 0.38 0.00 0.00
Current ratio 16.09 9.92 4.74
Net debt to EBITDA 1.53 1.15 1.01

Dividend

Metric CADL NVCT Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric CADL NVCT Biotechnology median
Market cap 705.50m 722.17m 168.63m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack